Dafna Bar-Sagi

List of Publications by Year
in descending order

53 papers	8,809 citations	117625 34 h-index	189892 50 g-index
56 all docs	56 docs citations	56 times ranked	11890 citing authors

#	Article	IF	Citations
1	Exploiting cancerâ€™s drinking problem: regulation and therapeutic potential of macropinocytosis. Trends in Cancer, 2022, 8, 54-64.	7.4	23
2	EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion. Cell, 2022, 185, 169-183.e19.	28.9	38
3	Metabolic reprogramming of tumor-associated macrophages by collagen turnover promotes fibrosis in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2119168119.	7.1	31
4	Exercise-induced engagement of the IL-15/IL-15RÎ± axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell, 2022, 40, 720-737.e5.	16.8	67
5	Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia. Nature Metabolism, 2022, 4, 724-738.	11.9	20
6	A novel target for combination immunotherapy in pancreatic cancer: IL-1Î² mediates immunosuppression in the tumour microenvironment. British Journal of Cancer, 2021, 124, 1754-1756.	6.4	7
7	Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy. Cell Reports, 2021, 36, 109578.	6.4	42
8	Integrated Systems Analysis of the Murine and Human Pancreatic Cancer Glycomes Reveals a Tumor-Promoting Role for ST6GAL1. Molecular and Cellular Proteomics, 2021, 20, 100160.	3.8	17
9	A bright future for KRAS inhibitors. Nature Cancer, 2020, 1, 25-27.	13.2	52
10	Macropinocytosis as a Key Determinant of Peptidomimetic Uptake in Cancer Cells. Journal of the American Chemical Society, 2020, 142, 14461-14471.	13.7	30
11	Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1018-1037.	9.4	104
12	Covalent Targeting of Ras G12C by Rationally Designed Peptidomimetics. ACS Chemical Biology, 2020, 15, 1604-1612.	3.4	20
13	Tumor Cellâ€“Derived IL1Î² Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer. Cancer Research, 2020, 80, 1088-1101.	0.9	195
14	ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis. Genes and Development, 2019, 33, 641-655.	5.9	20
15	Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis. Nature, 2019, 576, 477-481.	27.8	113
16	The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers. Molecular Cell, 2019, 73, 224-237.e6.	9.7	58
17	BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis. Oncogene, 2019, 38, 3316-3324.	5.9	55
18	Pre-neoplastic pancreas cells enter a partially mesenchymal state following transient TGF-Î² exposure. Oncogene, 2018, 37, 4334-4342.	5.9	14

#	Article	IF	Citations
19	Kras and Tumor Immunity: Friend or Foe?. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031849.	6.2	62
20	EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Developmental Cell, 2018, 45, 681-695.e4.	7.0	497
21	Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Cancer Immunology Research, 2017, 5, 182-190.	3.4	126
22	The G proteinâ€“coupled receptor GPR31 promotes membrane association of KRAS. Journal of Cell Biology, 2017, 216, 2329-2338.	5.2	24
23	Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nature Medicine, 2017, 23, 235-241.	30.7	263
24	Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer. Cell Reports, 2017, 20, 558-571.	6.4	273
25	Simulating Heterogeneous Tumor Cell Populations. PLoS ONE, 2016, 11, e0168984.	2.5	4
26	Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules. Cell, 2016, 167, 1803-1813.e12.	28.9	133
27	One-way membrane trafficking of SOS in receptor-triggered Ras activation. Nature Structural and Molecular Biology, 2016, 23, 838-846.	8.2	49
28	Î³Î´ T Cells Support Pancreatic Oncogenesis by Restraining Î±Î² T Cell Activation. Cell, 2016, 166, 1485-1499.e15.	28.9	266
29	IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. Cancer Discovery, 2016, 6, 247-255.	9.4	283
30	Histological Image Processing Features Induce a Quantitative Characterization of Chronic Tumor Hypoxia. PLoS ONE, 2016, 11, e0153623.	2.5	7
31	High-Content, Full Genome siRNA Screen for Regulators of Oncogenic HRAS-Driven Macropinocytosis. Assay and Drug Development Technologies, 2015, 13, 347-355.	1.2	12
32	Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein. Cancer Research, 2015, 75, 544-553.	0.9	673
33	Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response. Clinical Cancer Research, 2015, 21, 1243-1247.	7.0	43
34	Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response. Cancer Cell, 2014, 25, 243-256.	16.8	124
35	Determining the macropinocytic index of cells through a quantitative image-based assay. Nature Protocols, 2014, 9, 182-192.	12.0	168
36	E-Cadherin-Mediated Cell Coupling Is Required for Apoptotic Cell Extrusion. Current Biology, 2014, 24, 868-874.	3.9	83

#	Article	IF	Citations
37	Abstract B46: Stabilized helices targeting the RAS-SOS interaction as inhibitors of RAS-dependent cancer cell growth. , 2014, , .		0
38	Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature, 2013, 497, 633-637.	27.8	1,316
39	An Orthosteric Inhibitor of the RASâ€“SOS Interaction. The Enzymes, 2013, 34 Pt. B, 25-39.	1.7	15
40	MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. Journal of Experimental Medicine, 2012, 209, 1671-1687.	8.5	254
41	Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nature Communications, 2012, 3, 1168.	12.8	135
42	Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia. Cancer Cell, 2012, 21, 836-847.	16.8	589
43	An orthosteric inhibitor of the Ras-Sos interaction. Nature Chemical Biology, 2011, 7, 585-587.	8.0	270
44	Perturbation of cytoskeleton dynamics by the opposing effects of Rac1 and Rac1b. Small GTPases, 2010, 1, 89-97.	1.6	14
45	Regulation of HRas signaling by Rabexâ€5â€mediated ubiquitination. FASEB Journal, 2009, 23, 882.5.	0.5	0
46	Compartmentâ€dependent modulation of Ras ubiquitination. FASEB Journal, 2008, 22, 1053.1.	0.5	0
47	Structural Analysis of Autoinhibition in the Ras Activator Son of Sevenless. Cell, 2004, 119, 393-405.	28.9	251
48	Structural Evidence for Feedback Activation by RasÂ·GTP of the Ras-Specific Nucleotide Exchange Factor SOS. Cell, 2003, 112, 685-695.	28.9	390
49	Differential Activation of the Rac Pathway by Ha-Ras and K-Ras. Journal of Biological Chemistry, 2001, 276, 15609-15615.	3.4	148
50	The structural basis of the activation of Ras by Sos. Nature, 1998, 394, 337-343.	27.8	692
51	Crystal Structure of the Dbl and Pleckstrin Homology Domains from the Human Son of Sevenless Protein. Cell, 1998, 95, 259-268.	28.9	214
52	Coupling of Ras and Rac Guanosine Triphosphatases Through the Ras Exchanger Sos. Science, 1998, 279, 560-563.	12.6	432
53	Regulation of Sos Activity by Intramolecular Interactions. Molecular and Cellular Biology, 1998, 18, 880-886.	2.3	90